News
June,2023
NanoMedSyn will participate to the International Symposium on Inorganic and Environmental Materials ISIEM2023 in Montpellier, France. The symposium will focus...
Lire la suite
November, 2022
The 3rd Immune-Oncology World Congress Immuno-Oncology2022 will focus on the latest developments and findings in immuno-oncology therapy as well as targeted...
Lire la suite
October, 2022
Invest in Biomed, 7th edition. For innovative companies with high potential in healthtech, Eurobiomed continues its support.
Lire la suite
October,2022
Day of the cluster : Biotherapy Innovation Occitanie October 13, 2022 in Montpellier https://www.agence-adocc.com/biotherapie-innovation-occitanie/
Lire la suite
June, 2022
NanoMedSyn is co-organiser of the 2nd Symposium on delivery and target for pediatric tumors, on 23-24th June in Switzerland (Schwarzsee)....
Lire la suite
June, 2022
10th Antibody Industrial Symposium 2022 We are proud to announce our participation to the 10th Antibody Industrial Symposium 2022 (AIS2022)...
Lire la suite
In Memory of our former CEO- November, 2021
Henry-Vincent Charbonné (1953-2021)
Lire la suite
October, 2021
NanoMedSyn is classified as a DEEPTECH company by Bpifrance for its Innovative Therapeutic Targeting Technology.
Lire la suite
July, 2021
NanoMedSyn has signed a research agreement with the French National Research Agency within the framework of the "Plan France Relance...
Lire la suite
June, 2021
NanoMedSyn has been distinguished for its Growth Path by Bpifrance and joins the "Excellence" community.
Lire la suite
December, 2020
NanoMedSyn has signed a 3-year Innovation Contract with the Occitanie Region for a "Research and Development of New Targeted Drugs"...
Lire la suite
July, 2020
Dr. Marcel Garcia, co-founder and Scientific Director, is appointed President and Scientific Director of NanoMedSyn by the General Assembly. This...
Lire la suite
June, 2019
This article demonstrates the involvement of acid phosphatases in the higher efficacy of AMFA-labelled enzyme therapy. J Cell Mol Med....
Lire la suite
March, 2018
Shire and NanomedSyn enter into research agreement for potential lysosomal storage disorder treatment. This collaboration was stopped in September 2019....
Lire la suite
October, 2017
NanoMedSyn develops an efficient treatment for refractory Pompe disease published by Journal of Controlled Release. J Control Release 2017, 269:15-23.
Lire la suite
October, 2016
First NanoMedSyn studies to improve Pompe disease treatment published by Angewandte. Angew Chem Int Ed Engl. 2016 DOI: 10.1002/anie.201607824R2
Lire la suite
September, 2016
Orphan designation was granted by European commission for the recombinant GAA-AMFA developed by NanoMedSyn for the treatment of Pompe's disease....
Lire la suite
June, 2016
Le Grand Prix « Sciences de la Vie » est décerné à NanoMedSyn au Sénat lors de la finale du 16e concours...
Lire la suite